ANTARES PHARMA, INC. ATRS Cash Flow

Antares pharma, inc. (ATRS)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash flows from operating activities:
Net loss
1,156	-2,027	-588	-3,567	-5,861	-6,515	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-21,418	-	-26,465	-26,082	-21,527	-20,659	-24,105	-25,553	-33,144	-35,151	-30,713	-29,887	-25,892	-20,506	-19,883	-17,057	-14,761	-11,427	-6,569	-4,334	-3,081	-4,387	0	0	0
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation expense
7,082	6,470	5,917	5,877	5,308	4,927	4,774	4,256	3,939	3,490	3,004	2,526	2,520	2,520	2,896	3,285	3,461	3,659	3,375	3,072	2,737	2,624	2,799	2,756	2,605	2,435	2,095	1,934	1,965	2,025	1,848	1,937	1,912	1,872	0	0	0
Depreciation and amortization
2,449	2,557	2,832	2,855	2,798	2,724	2,392	2,340	2,214	2,104	2,009	1,940	1,941	1,861	1,771	1,692	1,604	1,570	1,520	1,489	1,378	1,224	1,078	837	643	493	341	315	259	231	224	166	173	168	0	0	0
Other
172	95	137	79	55	51	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of premiums and discounts on investment securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-13	-13	-11	-10	-7	-6	-6	-20	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Accounts receivable
1,633	16,095	18,450	10,560	17,290	7,099	5,335	5,001	4,596	2,798	1,582	-1,230	-89	1,138	2,002	3,848	3,766	4,423	4,285	3,380	559	2,478	-1,137	-1,269	1,914	-1,198	1,349	1,695	316	-310	72	1,336	-190	1,300	0	0	0
Inventories
4,256	4,975	5,820	5,147	4,040	2,667	3,689	3,190	3,434	4,304	1,966	1,135	2,330	351	1,765	2,692	72	564	1,214	680	2,340	2,948	6,188	7,306	6,400	5,460	919	146	-582	118	553	479	972	629	0	0	0
Contract assets
5,484	2,793	3,424	3,374	4,013	4,937	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other assets
-555	655	-6	1,238	1,938	324	125	224	548	942	1,300	-1,029	-1,657	-1,922	-1,672	-156	129	934	1,077	1,801	2,011	617	96	165	308	1,222	-136	484	500	177	770	210	-22	156	0	0	0
Deferred costs
-	-	-	-	-	-	-	-	-	-	0	0	-337	-	1,441	1,197	340	-715	-1,170	-118	1,163	1,538	0	0	0	-	-	0	0	-	-	730	985	-212	0	0	0
Other assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	821	2	2	-6	18	0	0	0	-	-	-	0
Accounts payable
2,268	926	8,315	5,064	8,751	5,164	-706	-1,636	-2,111	-1,522	252	-1,493	2,283	2,859	5,555	5,631	-1,387	-3,495	-2,833	-280	3,439	2,688	920	-871	1,076	2,528	1,790	3,204	245	724	631	-308	952	365	0	0	0
Accrued expenses and other liabilities
3,862	4,888	5,726	3,768	5,103	5,029	2,729	2,777	-202	1,122	114	-902	-606	-582	523	1,199	3,571	906	-147	-1,706	-254	221	1,192	4,670	2,750	2,534	2,229	687	22	687	0	0	0	-	-	-	-
Deferred revenue
508	718	400	-481	-458	-1,977	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued expenses and other current liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	0	-805	-	4,300	3,925	-3,975	-6,030	-8,419	-8,641	-2,251	5,487	9,606	10,220	9,774	3,196	-873	-1,260	-1,575	-3,340	-1,775	-710	-953	1,543	0	0	0
Net cash provided by (used in) operating activities
6,955	-10,615	-16,647	-18,422	-23,283	-17,322	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5,565	-4,971	-1,734	-1,926	0	0	0
Cash flows from investing activities:
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-15,213	-	-14,044	-17,019	-21,504	-28,199	-31,706	-33,057	-30,030	-26,333	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-
Proceeds from sale of assets
-	-	-	-	-	7,500	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of equipment, molds, furniture and fixtures
2,600	2,350	1,602	1,622	1,184	854	814	974	801	1,167	1,480	2,853	3,540	4,880	4,908	4,106	5,520	5,643	6,846	7,836	6,424	4,663	3,388	1,853	2,108	2,743	3,015	4,753	3,814	3,256	2,548	489	457	350	0	0	0
Purchases of investment securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21,129	24,207	33,250	36,276	30,166	0	0	0	-	-	-	0
Proceeds from maturities of investment securities
0	-	-	-	-	-	-	-	-	-	-	-	-	15,000	12,000	6,000	6,000	6,000	9,000	15,000	21,000	24,000	0	0	0	-	-	-	-	12,000	0	0	0	-	-	-	0
Additions to patent rights
-	-	-	-	-	40	58	63	102	101	106	144	103	127	138	121	147	1,043	1,536	1,697	1,875	989	686	583	424	420	156	193	261	244	361	259	206	231	0	0	0
Net cash provided by (used in) investing activities
-14,245	-19,995	898	857	8,536	11,606	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Cash flows from financing activities:
Net cash provided by (used in) investing activities
-	-	-	-	-	-	-	-	-	-	-	-	8,356	-	6,952	1,771	-14,706	-15,724	-14,420	-9,571	12,700	18,346	13,913	21,551	15,455	-293	-9,379	-29,197	-31,352	-21,667	0	0	0	-	-	-	-
Proceeds from issuance of common stock, net
-	7,781	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options
4,326	4,405	782	667	796	474	512	517	1,463	1,816	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,105	4,478	3,096	3,460	2,326	2,734	6,957	11,099	11,579	9,649	5,768	1,523	6,020	0	0	0
Taxes paid related to net share settlement of equity awards
1,320	1,131	1,077	1,471	821	543	0	0	0	-	-	-	-	84	64	84	111	88	87	67	50	154	154	154	115	104	104	104	104	28	0	0	0	-	-	-	0
Net cash (used in) provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	432	-	-8	-317	42,770	42,794	42,959	44,736	1,817	2,950	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-
Effect of exchange rate changes on cash
-	-	-	-	-	-	-	-	-	-	-	-	-1	-	1	-0	-0	-1	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by (used in) financing activities
17,866	25,919	29,464	28,955	14,874	7,045	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,620	5,506	22,542	27,067	0	0	0
Effect of exchange rate changes on cash
-	-	-	-	-	1	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase (decrease) in cash and cash equivalents
10,576	-4,691	13,714	11,389	127	1,330	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effect of exchange rate changes on cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	11	26	-12	1	-26	-52	-9	-25	0	0	0
Net decrease in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	0	0	-	30,800	17,941	19,958	32,739	-4,958	-15,354	5,101	9,510	0	0	0
Net increase (decrease) in cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental disclosure of cash flow information:
Cash paid for interest
3,366	3,025	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental disclosure of non-cash investing activities:
Purchases of equipment, molds, furniture and fixtures recorded in accounts payable and accrued expenses
1,702	970	874	121	275	49	3	-198	119	40	-35	-597	-987	424	1,150	1,510	392	641	635	409	2,133	1,118	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Additions to patent rights recorded in accounts payable and accrued expenses
-	-	-	-	-	-	-	4	-32	10	27	30	86	45	0	0	0	-	-	-148	211	949	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-